Celldex Therapeutics (CLDX) Total Current Liabilities (2010 - 2026)

Celldex Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $51.5 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 60.76% year-over-year to $51.5 million; the TTM figure through Mar 2026 stood at $51.5 million (up 60.76% YoY), while the FY2025 annual figure was $51.0 million, up 29.09% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $51.5 million, up from $51.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $51.5 million in Q1 2026, with the low at $14.6 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $29.9 million (2022), against an average of $29.9 million.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 106.72% in 2022, then slumped 47.76% in 2023.
• Celldex Therapeutics' Total Current Liabilities stood at $18.6 million in 2022, then surged by 67.25% to $31.1 million in 2023, then grew by 26.91% to $39.5 million in 2024, then grew by 29.09% to $51.0 million in 2025, then gained by 0.94% to $51.5 million in 2026.
• Business Quant data shows CLDX's Total Current Liabilities at $51.5 million in Q1 2026, $51.0 million in Q4 2025, and $46.5 million in Q3 2025.